Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
| ▸ | FPR1 | P21462 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CCR3 | P51677 | 1/20 | 0.30 |
| ▸ | APOL1 | O14791 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26515041 | 1.00 | SIGMAR1 (0.33) | SIGMAR1CRBNSMYD3GPR52FPR1 | |
| SCHEMBL26089505 | 0.90 | SIGMAR1 (0.40) | SIGMAR1CRBNSMYD3CCR3APOL1 | |
| SCHEMBL26090464 | 0.85 | LMNA (0.37) | SIGMAR1CRBNSMYD3APOL1 | |
| SCHEMBL26090446 | 0.85 | FPR2 (0.39) | FPR1FPR2POLBCCR3 | |
| SCHEMBL26435659 | 0.85 | FPR2 (0.39) | FPR1FPR2POLBCCR3 | |
| SCHEMBL26090105 | 0.83 | LMNA (0.36) | CRBNSMYD3 | |
| SCHEMBL26087755 | 0.81 | CRBN (0.41) | SIGMAR1CRBNSMYD3 | |
| SCHEMBL26090376 | 0.81 | CACNA1H (0.36) | CRBNFPR1FPR2POLB | |
| SCHEMBL30349451 | 0.81 | CACNA1H (0.36) | CRBNFPR1FPR2POLB | |
| SCHEMBL26090242 | 0.81 | CRBN (0.35) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CRBN, GSPT1, GSPT2 | SIGMAR1 3933/4885CRBN 1/4885SMYD3 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.